Maravai LifeSciences Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Maravai LifeSciences reported Q3 2026 revenue of $45.9 million, up 10% year over year.
- TriLink revenue increased 12%; mRNA revenue grew 28%, with GMP consumables up 30% and discovery mRNA up 27%.
- CDMO revenue grew 8%, while specialty chemistry declined 4% because some large Q3 2025 orders did not repeat.
- Cygnus revenue grew 8%, marking its 6th consecutive quarter of year-over-year growth.
- Adjusted gross margin expanded more than 1,700 basis points year over year to 57.7%, and adjusted EBITDA improved by $16.6 million to $5.8 million.
- GAAP net loss before non-controlling interest was $24 million, compared with $45.1 million in the prior-year period; adjusted EPS was a loss of $0.03 versus a loss of $0.08 per share last year.
- Maravai ended the quarter with $73 million in cash and $147.2 million in debt.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Deb Hart.
Please go ahead. Good afternoon, everyone.
Thanks for joining us for our third quarter 2026 earnings call. The press release and the slides that accompany today's call are available at investors.maravai.com. As you can see from the agenda on slide two, our CEO, Bernd Brust, will provide a business update, and our CFO, Raj Asarpota, will review our financial results. Dr. Chanfeng Zhao, our Chief Scientific Officer, and Kurt Oreshack, our Executive Vice President and General Counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from expectations, and we undertake no obligation to update them. We refer you to slide three for details on our forward-looking statements and slide four for our use of non-GAAP financial measures.
The press release and the slides provide reconciliations to the most directly comparable GAAP measures, and we also post reconciling schedules to our investor website. Please also refer to the risk factors in Maravai's annual report on Form 10-K for 2025, our subsequent quarterly reports on Form 10-Q, and our other SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I'll turn the call over to Bernd.
Good afternoon, and thank you for joining us. We are pleased with our third quarter performance, which builds on the momentum we established in the first half of the year. Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy. During the quarter, we generated revenue of $45.9 million, representing 10% year-over-year growth. TriLink revenue increased 12%, led by strong demand for our mRNA products. mRNA revenue was up 28% year-over-year. Within mRNA, GMP consumables grew 30%, and discovery mRNA grew 27%. We had no high-volume CleanCap revenue for commercial-phase COVID vaccine programs in the quarter. CDMO revenue grew 8%, while specialty chemistry was down 4%, as some large orders from Q3 of 2025 did not repeat in the quarter this year. Cygnus also delivered a solid quarter, with revenue growing at 8%.
This is the sixth consecutive quarter of year-over-year growth for Cygnus. From a profitability standpoint, adjusted gross margin expanded more than 1,700 basis points year-over-year to 57.7%, while adjusted EBITDA improved by $16.6 million to $5.8 million. These results reflect higher revenue, a favorable product mix, and the benefits of the operating model we've built over the past year. Now, let's turn to slide seven and highlight some of the landmark clinical progress we are seeing in our largest, most strategic part of the business, the mRNA market. While the Moderna-Merck phase III cancer vaccine for melanoma has captured the headlines, there were several other mRNA advancements during Q3 that marked an equally transformative period for our field. In rare metabolic disease, an investigational mRNA protein replacement therapy for a severe inherited liver disease with limited treatment options showed meaningful phase II clinical activity across key metabolic biomarkers.
This is mRNA as a protein replacement platform, not a vaccine, and the addressable population extends across a broad class of rare inherited enzyme deficiencies. In gene editing, a single-dose LNP-delivered base editing therapy for a severe inherited condition affecting the lungs and liver entered a global pivotal cohort intended to support a request for U.S. accelerated approval. Phase I/II data at 18 months showed sustained correction above clinically meaningful thresholds. It is the first genetic medicine to reach pivotal stage development for this condition. In infectious disease, a major biopharma company announced plans to initiate a phase III trial for an mRNA flu vaccine targeting both HA and NA antigens, the first phase III of its kind. The program carries FDA Fast Track designation, and the sponsor has said that it expects preliminary data next year and to complete its regulatory submission in 2028.
Not every program will succeed, and we did see a couple of mRNA cancer vaccine programs recently report disappointing results. That is the nature of drug development and why a broad, diverse pipeline like ours matters. We are supporting over 50 GMP customers in 2026 and estimate each customer has two to three clinical programs on average. As programs progress from early-stage studies to pivotal trials and commercialization, they typically require greater volumes of higher-quality GMP-grade materials, directly linking this clinical progress to our long-term growth. We at Maravai are proud of the key role that our customers, partners, and employees are playing in bringing mRNA therapies to patients. Now let's turn to slide eight and discuss progress against our three strategic priorities: innovation, commercial execution, and operational excellence. Innovation remains the foundation of our long-term growth strategy, and this quarter we made meaningful progress.
At TriLink, ModTail continues to build momentum. We continue to expect GMP-grade ModTail to launch before year-end, and customer interest remains strong. As of the end of Q3, we had more than 180 customers actively using this technology, up from 125 as of the end of Q2. Adoption is coming through new accounts, repeat orders, and expanding use across applications. Beyond our current commercial offerings, we are also building the next wave of mRNA capping innovation at TriLink. Within our R&D Vault, we have available a broad library of novel caps, each with differentiated cap chemistry with the potential to optimize mRNA for different applications. We are now introducing this library to our customers and are working with them to determine which caps suit their application best. This approach lets customers select their cap based on its therapeutic impact for their specific program.
We believe this is a competitive differentiator and valuable resource for our customer. At Cygnus, our recently launched Residual Protein A Mix-N-Go Kit continues to gain traction. Although still small, revenue has increased each month since its launch in June. These kits reduce the complexity of the assay and shorten the time to result over traditional protein A ELISAs. Cygnus also recently expanded its innovation portfolio through the launch of a new SV40 particle kit. This is the third kit introduced in the MockV franchise and is tailor-made for those working on gene therapy products, specifically AAV. It will enable bioprocess scientists to analyze the efficacy of their downstream viral filtration step at a fraction of the cost and time associated with live viral clearance studies. Under innovation, we will also start talking about AI initiatives.
Now, beyond new products, our innovation efforts also extend to helping customers design better mRNA candidates. AI is reshaping that process, and TriLink is positioned to participate not just as a manufacturing partner, but also as a design partner. Most of the AI conversation in drug discovery focuses on identifying the right sequence, but a sequence is not a drug. It becomes a drug only when protein is expressed in the right amount, in the right tissue, for the right duration, and those variables are determined at the mRNA design level. That is the design space where TriLink's expertise is uniquely relevant. Our proprietary AI-assisted mRNAbuilder enables rapid prototyping of mRNA candidates to test diverse combinations of cap analogs, chemistry modifications, and sequence designs to let customers refine constructs before manufacturing. These capabilities are gaining commercial traction.
The mRNAbuilder customer base is growing and has become a significant channel for new customer acquisition, particularly in early-stage research. mRNAbuilder expands TriLink's role from reagent supplier to mRNA design service provider. We believe this broader role gives us a lasting competitive advantage. We are confident our R&D engine throughout TriLink and Cygnus is robust, and we continue to innovate through new product introduction and our AI initiatives with the goal to help customers' drug development programs succeed. We also continue to strengthen our intellectual property portfolio. TriLink received an additional China patent in Q3, adding broad composition of matter protection to our intellectual property protection. Together with the patent received in June, these two China patents create a multi-layered intellectual property asset covering both the process of making CleanCap capped RNA and the fundamental molecular structures at the core of that process. Moving on to commercial execution.
Our commercial go-to-market strategy continues to translate into results. In discovery mRNA, we added more than 70 new customers in Q3, exceeding our prior record from Q2. We saw 27% growth in discovery mRNA, supported by continued strength in research funding and our commercial and product initiatives. Discovery activity continues to strengthen, which we believe will create future growth opportunities for our GMP pipeline as customer programs advance into clinical development. In Q3, four additional discovery customers transitioned to clinical-stage GMP customers as they progressed toward their phase I clinical trials, bringing year-to-date RUO to GMP conversions to 10 and surpassing our initial full-year target of nine new GMP customers. Cygnus continues to deliver steady performance through its purpose-built portfolio for HCP bioprocess impurity testing.
Throughout TriLink and Cygnus, we continue to broaden our commercial presence around the world and recently established an in-country sales presence in China to support further market expansion. Operational excellence remains a key driver of our financial performance, and you can see that in our results. The actions under our restructuring are complete, the cost base has been reset, and the infrastructure we have in place is built to scale. Leveraging our in-place infrastructure, we expect to drive further margin improvements and improve financial performance as we grow. AI is now a meaningful part of how we operate. Across Maravai, more than 40% of our employees are weekly active AI users. A number that reflects genuine integration into day-to-day workflows, not a pilot. We believe that adoption is translating into real operating improvements. Let me give you a few examples of what this looks like in practice.
In engineering, AI-assisted analysis helped optimize compressor operating settings, reducing equipment runtime and energy consumption. This illustrates how targeted applications can improve efficiency across our operations. Our finance team is using AI to expand scenario analysis, research, and assumption testing. This allows us to bring more analytical work in-house and support the business without adding headcount. We're using customer purchasing trends to identify customers ready to move into GMP products and larger programs that may benefit from our CDMO services. This helps our commercial teams focus their outreach and connect customers with the right capabilities as their programs advance. In our R&D organization, we have compressed what used to take days into hours. The common thread is simple. Our scientists are spending less time on information gathering and more time on the creative and scientific work that accelerates innovation. To summarize, Q3 was another quarter of strong execution.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
